Evonik Evonik

X

Find Elocalcitol manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Ro 26-9228
Also known as: 199798-84-0, Bxl 628, Elocalcitol [inn], Bxl-628, Ro-26-9228, 2wds5f2v6q
Molecular Formula
C29H43FO2
Molecular Weight
442.6  g/mol
InChI Key
LRLWXBHFPGSUOX-GJQYOBCGSA-N
FDA UNII
2WDS5F2V6Q

Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).
1 2D Structure

Ro 26-9228

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1R,3Z,5S)-3-[(2E)-2-[(3aS,7aS)-1-[(E,2S)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol
2.1.2 InChI
InChI=1S/C29H43FO2/c1-6-29(32,7-2)17-8-10-20(3)25-14-15-26-22(11-9-16-28(25,26)5)12-13-23-18-24(31)19-27(30)21(23)4/h8,12-14,17,20,24,26-27,31-32H,4,6-7,9-11,15-16,18-19H2,1-3,5H3/b17-8+,22-12+,23-13-/t20-,24+,26-,27-,28+/m0/s1
2.1.3 InChI Key
LRLWXBHFPGSUOX-GJQYOBCGSA-N
2.1.4 Canonical SMILES
CCC(CC)(C=CCC(C)C1=CCC2C1(CCCC2=CC=C3CC(CC(C3=C)F)O)C)O
2.1.5 Isomeric SMILES
CCC(CC)(/C=C/C[C@H](C)C1=CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)F)O)C)O
2.2 Other Identifiers
2.2.1 UNII
2WDS5F2V6Q
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bxl-628

2. Bxl628

2.3.2 Depositor-Supplied Synonyms

1. 199798-84-0

2. Bxl 628

3. Elocalcitol [inn]

4. Bxl-628

5. Ro-26-9228

6. 2wds5f2v6q

7. Ro 26-9228

8. (1r,3z,5s)-3-[(2e)-2-[(3as,7as)-1-[(e,2s)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol

9. Bxl628

10. Unii-2wds5f2v6q

11. Elocalcitol [mart.]

12. Gtpl2785

13. Schembl12932254

14. Zha79884

15. Zinc4802676

16. 1alpha-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epi-cholecalciferol

17. Akos025312296

18. Db06194

19. Hy-32345

20. Cs-0001526

21. J3.510.012a

22. E98793

23. 798e840

24. Q27077174

25. 1alpha-fluoro-16-ene-20-epi-23-ene-26,27-bishomo-25-hydroxyvitamin D3

26. (1r,5s,z)-3-((e)-2-((3as,7as)-3-((s,e)-6-ethyl-6-hydroxyoct-4-en-2-yl)-3a-methyl-3a,4,5,6-tetrahydro-1h-inden-7(7ah)-ylidene)ethylidene)-5-fluoro-4-methylenecyclohexanol

27. 1s,3r,5z,7e,23e)-1-fluoro-26,27-dihomo-9,10-secocholesta-5,7,10(19),16,23-pentaene-3,25-diol

28. Cyclohexanol, 3-((1-(5-ethyl-5-hydroxy-1-methyl-3-heptenyl)-3,3a,5,6,7,7a-hexahydro-7a-methyl-4h-inden-4-ylidene)ethylidene)-5-fluoro-4-methylene-, (3as-(1(1r*,3e),3aalpha,4e(1s*,3z,5r*),7abeta))-

29. Cyclohexanol, 3-((2e)-((3as,7as)-1-((1s,3e)-5-ethyl-5-hydroxy-1-methyl-3-heptenyl)-3,3a,5,6,7,7a-hexahydro-7a-methyl-4h-inden-4-ylidene)ethylidene)-5-fluoro-4-methylene-, (1r,3z,5s)-

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 442.6 g/mol
Molecular Formula C29H43FO2
XLogP35.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count3
Rotatable Bond Count7
Exact Mass442.32470877 g/mol
Monoisotopic Mass442.32470877 g/mol
Topological Polar Surface Area40.5 Ų
Heavy Atom Count32
Formal Charge0
Complexity813
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count3
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in benign prostatic hyperplasia, urinary incontinence, prostate disorders, and infertility.


Treatment of benign prostatic hyperplasia


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY